Update: Funding for the next level
Regeneus has raised A$6m in equity to accelerate the development and commercialisation of a number of its products. With a further A$3.7m R&D tax rebate just received, the company is well placed to advance its stem cell and cancer vaccine franchises. Of particular note, capital is now available to complete the preclinical work required for Progenza (allogeneic stem cells for osteoarthritis) and a human cancer vaccine, and initiate first-in-man clinical studies with both candidates in H115. Adjusting for the recent financing, our valuation is now A$148m, or A$0.71 per share.Regeneus is engaged in the development and commercialization of proprietary adipose-derived stem cell technologies used by physicians and veterinarians to treat musculoskeletal conditions in humans and animals.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.